Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Untersuchung von Gehirnmechanismen, die am altersbedingten Harnkontinenzmechanismus beteiligt sind

1. Oktober 2026 aktualisiert von: Becky Clarkson, University of Pittsburgh

Urge urinary incontinence (UUI) is a common problem in older people which vastly reduces quality of life, yet the cause and mechanism of disease are not well understood. This study will characterize brain control of the bladder in young and old continent individuals and age-matched incontinent counterparts. This will expand the investigators current knowledge of how the brain controls the bladder, how that control changes with age and disease, and suggest new targets to guide development of better treatment.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Current data suggest that bladder control comprises 3 cerebral circuits that maintain continence by suppressing the voiding reflex in the midbrain. In the UUI phenotype that responded to BFB (Biofeedback assisted pelvic floor muscle therapy), the mechanism involved enhancing deactivation of the first brain circuit (medial prefrontal cortex, mPFC) which resulted in less activation of the second circuit (which includes the midcingulate cortex). In the phenotype that was resistant to BFB, no brain changes were seen. Although the investigators have an emerging picture of the brain's role in UUI, the investigators have only rudimentary understanding of what is 'normal', i.e. how the brain normally controls the bladder. Moreover, the investigators do not know whether this control mechanism is the same across the lifespan, or whether it changes owing to the impact of aging. Thus, the investigators aims are to characterize the brain's normal role in bladder control in both young and old people, to determine the changes in brain structure and function that lead to bladder control failure (UUI), and to examine how such changes differ between young and old individuals. To address the aims, the investigators will utilize detailed neuroimaging to evaluate 80 asymptomatic women and 80 women with UUI, each group divided into young (18-45) and old (65+ years) individuals. The study will enable the investigators to define the brain's key structures, functional activity, and mechanisms involved in normal bladder control, and to identify the differences in these elements among those with UUI, both young and old.

By elucidating the mechanisms that mediate the brain's control (and loss of control) of bladder function, the proposed study should enhance the investigators working model, deepen the understanding of the impact of aging, and identify better targets for the treatment of UUI. It may thereby enable scientists to develop novel and more effective new therapies based on the revolution in neuroscience-and more hope for UUI sufferers.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

217

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Pennsylvania
      • Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
        • University of Pittsburgh

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria:

  • 'Old' (community-dwelling, mentally and functionally intact ambulatory women aged 65+ years) or 'Young' (equivalent women aged 18-45)
  • 'Wet' (those who meet the International Continence Society definition of urgency urinary incontinence (urinary leakage accompanied by a sudden, strong urge to void which is difficult to defer) >5 times per week, for 3 months despite treatment for reversible causes (e.g., Urinary tract infection) and confirmed by a mean of one episode per day of UUI on 3-day bladder diary) or 'Dry' (women without current or past UUI or other lower urinary tract symptoms.) Infrequent stress incontinence of a small amount is acceptable.
  • Urge-predominant mixed incontinence is acceptable provided the subject is able to differentiate between stress incontinence (SUI - leakage that coincides instantaneously with cough, laugh, exercise) and urgency incontinence, i.e., leakage accompanied by a sudden strong urge to void that is difficult to defer.
  • Those with current or previous use of anticholinergic/beta-3 agonist medications will be considered for the study if they are willing to go through a washout period of at least 4 weeks of duration.

Exclusion Criteria:

Dry Groups

  • Current or prior treatment for UUI
  • Leakage on bladder diary not ascribed to minimal SUI (see bullet above)

All Groups: 'Wet' or 'Dry'; 'Young' or 'Old'

  • Cognitive impairment:

    • MoCA<26
    • inability to perform a voiding diary/pad test
    • inability to reliably take daily medication
    • inability to comply with fMRI testing
  • Impaired mobility

    o Timed up and go test ≥ 12 secs

  • Medical instability:

    • severe uncontrolled hypertension >180mmHg systolic or >100mmHg diastolic
    • potential major changes in medical management over the course of the study period (i.e. upcoming surgery/treatment)
    • frailty according to the Fried criteria
  • MRI incompatibility:

    • contraindicated metal implants
    • claustrophobia
    • unidentified/untested compatibility of metal implants
  • Medication incompatibility:

    • allergy to study medication (all prophylactic antibiotic choices)
    • interaction of prophylactic antibiotic choices with current medications
    • expected change in medication during the study
  • Neurological conditions:

    • spinal cord injury;
    • multiple sclerosis
    • clinically apparent lesions (e.g. lacunae associated with stroke)
    • prior stroke
    • Parkinson's Disease/ALS/MSA
    • any clinically apparent neurological condition
  • Lower urinary tract comorbidities/treatment:

    • history of pelvic irradiation
    • bladder or advanced uterine cancer
    • possible urethral obstruction (advanced prolapse [POP-Q>II] or Qmax<12 ml/s on free flow)
    • urinary retention (PVR >200 ml)
    • Interstitial Cystitis/Bladder Pain Syndrome
    • artificial sphincter implant
    • Botox treatment for UUI within 1 year
    • Neuromodulation treatment for UUI
  • Other comorbidities:

    • uncontrolled depression (PHQ-9 ≥10)

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Sonstiges
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Brain functional MRI with simplified urodynamics

Females with urgency urinary incontinence

Structural:

MPRAGE provides a structural image, which is used for coregistration of subjects. Structural scans are then performed including Diffusion Spectrum Imaging (DSI; microstructural), and Fluid-attenuated inversion recovery (FLAIR; white matter specific) scans.

Functional:

With about 50 ml in the bladder, resting state functional BOLD measurements are made, followed by functional whole-brain images while a small amount of saline is infused and withdrawn from the bladder, in 2 blocks of 4 repetitions each. Each repetition starts with a 12-scan pause, followed by infusion (6 scans = 12 s), pause (6 scans), and withdrawal (6 scans). Each block of 4 repetitions is completed by a 6 scan pause during which scanning continues. 24 ml is infused at 120 ml/min, and slightly less is withdrawn to avoid accommodation.This is repeated on an empty and full bladder along with a resting state image.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - mPFC
Zeitfenster: Baseline

BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined mPFC (medial prefrontal cortex) region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit.

The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition.

Baseline
BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - Left Insula
Zeitfenster: Baseline

BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined insula region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit.

The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition.

Baseline
BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - dACC
Zeitfenster: Baseline

BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined dACC (dorsal anterior cingulate cortex) region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit.

The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition.

Baseline

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Becky Clarkson, PhD, University of Pittsburgh

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

14. Dezember 2020

Primärer Abschluss (Tatsächlich)

31. Juli 2025

Studienabschluss (Tatsächlich)

1. April 2026

Studienanmeldedaten

Zuerst eingereicht

1. Oktober 2020

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

21. Oktober 2020

Zuerst gepostet (Tatsächlich)

22. Oktober 2020

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

5. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

1. Oktober 2026

Zuletzt verifiziert

1. Juli 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • STUDY20080217
  • R01AG065288 (US NIH Stipendium/Vertrag)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

All of the individual participant data collected during the trial, after de-identification may be shared with other researchers.

IPD-Sharing-Zeitrahmen

Following publication, no end date

IPD-Sharing-Zugriffskriterien

Any purpose

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF
  • CSR

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .